Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements and body weight in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. RESULTS: HbA1c level was reduced 0.34–0.54% (3.7–5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide −0.20% [95% CI −0.32; −0.07]; 1.2 mg liraglutide −0.15% [95% CI −0.27; −0.03]; 0.6 mg liraglutide −0.09% [95% CI −0.21; 0.03]). Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]). Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide −4.9 kg [95% CI −5.7; −4.2]; 1.2 mg liraglutide −3.6 kg [95% CI −4.3; −2.8]; 0.6 mg liraglutide −2.2 kg [95% CI −2.9; −1.5]). The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglutide 1.8 mg only (event rate ratio 2.22 [95% CI 1.13; 4.34]). CONCLUSIONS: Liraglutide added to insulin therapy reduced HbA1c levels, total insulin dose, and body weight in a population that was generally representative of subjects with type 1 diabetes, accompanied by increased rates of symptomatic hypoglycemia and hyperglycemia with ketosis, thereby limiting clinical use in this group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The largest clinical trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide 1.8 mg daily, and results showed modest A1C reductions ($0.4%), decreases in weight ($5 kg), and reductions in insulin doses (71,72).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [71]
In the citing paper
“However, increased rates of hypoglycemia and ketosis were shown.”
In the citing paper
“The largest clinical trials in people with type 1 diabetes were conducted with liraglutide and showed decreases in HbA 1c at daily doses of 1.8 mg (0.2-0.4% [2-4 mmol/mol]), decreases in weight (5 kg), and reductions in insulin doses (257,258).”
In the citing paper
“GLP1 receptor agonists reduce bodyweight and insulin dose, with modest improvements in glycaemic control.[93][94][95][96]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [93]
In the citing paper
“Adding SGLT2 inhibitors at a lower than usual dose to insulin therapy in T1DM may reduce glucose variability and facilitate glucose control, thereby reducing insulin doses and hypoglycaemia.803”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [803]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 3×
“****EAC-confirmed malignant neoplasms were all skin cancers (two malignant melanomas; one basal cell carcinoma) using ADA classification of hypoglycemia (13).”
BackgroundMethodInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“drate levels may be reduced as a result of urinary excretion (23,24).”
BackgroundWeinstock, R. S., Xing, D., Maahs, D. M., Michels, A., Rickels, M. R., Peters, A. L., Bergenstal, R. M., Harris, B., DuBose, S. N., Miller, K. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1589 · Cited by 338
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 283
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Self-citationDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“…trial design or on top of capped insulin regimens, resulted in weight loss and reduction in insulin dose, but only modest reduction in A1c, and increased rates of gastrointestinal adverse events (AEs), ketoacidosis, and symptomatic hypoglycemia (Ahrén et al., 2016; Mathieu et al., 2016).”
Background2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363
Self-citationDandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 293
Self-citationAhrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Self-citationNew frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
“2%), insulin doses and weight in subjects with T1D andat the expense of increased hypoglycemia and hyperglycemia with ketosis (Mathieu et al., 2016).”
BackgroundBuse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
Self-citation9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Obesity in people living with type 1 diabetes
Van der Schueren, B., Ellis, D., Faradji, R. N., Al-Ozairi, E., Rosen, J., & Mathieu, C. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00246-1 · Cited by 185
Self-citationDanne, T., Cariou, B., Banks, P., Brandle, M., Brath, H., Franek, E., Kushner, J. A., Lapuerta, P., McGuire, D. K., Peters, A. L., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0342 · Cited by 186
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Cefalo, C. M. A., Cinti, F., Moffa, S., Impronta, F., Sorice, G. P., Mezza, T., Pontecorvi, A., & Giaccari, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0828-y · Cited by 174
Cardiovascular Risk in Type 1 Diabetes Mellitus
Schofield, J. D., Ho, J. H., & Soran, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0612-8 · Cited by 177
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 173
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
“ple with type 1 diabetes responding better to liraglutide treatment in a post hoc analysis of the ADJUNCT ONE trial.(61) This is in line with a subsequent retrospective analysis conducted in 11 people with type”
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Double diabetes—when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition
Bielka, W., Przezak, A., Molęda, P., Pius‐Sadowska, E., & Machaliński, B. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02145-x · Cited by 172
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
The emergence of obesity in type 1 diabetes
Kueh, M. T. W., Chew, N., Al‐Ozairi, E., & le Roux, C. W. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01429-8 · Cited by 144
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Anson, M., Zhao, S. S., Austin, P., Ibarburu, G. H., Malik, R. A., & Alam, U. (2023) · Diabetologia · doi:10.1007/s00125-023-05975-8 · Cited by 103
Edwards, K., Li, X.-L., & Lingvay, I. (2022) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgac618 · Cited by 85
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., José, P. S., Rubio, M. Á., & Lecube, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s223618 · Cited by 111
New advances in type 1 diabetes
Subramanian, S., Khan, F., & Hirsch, I. B. (2024) · BMJ · doi:10.1136/bmj-2023-075681 · Cited by 88
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
Ghanim, H., Batra, M., Green, K., Abuaysheh, S., HEJNA, J. M., Makdissi, A., Borowski, R. S., Kuhadiya, N. D., Chaudhuri, A., & Dandona, P. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14090 · Cited by 96
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Garg, S. K., Kaur, G., Haider, Z., Rodriquez, E., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0490 · Cited by 78
SGLT inhibitor adjunct therapy in type 1 diabetes
McCrimmon, R. J., & Henry, R. R. (2018) · Diabetologia · doi:10.1007/s00125-018-4671-6 · Cited by 79
Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13911 · Cited by 80
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 162
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Mathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., Thorén, F., Scheerer, M. F., Iqbal, N., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14060 · Cited by 71
Self-citationJohansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Frandsen, C. S., Forman, J. L., Wewer Albrechtsen, N. J., Holst, J. J., Pedersen-Bjergaard, U., Madsbad, S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30030-9 · Cited by 70
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Prevention of Cardiovascular Disease in Type 1 Diabetes
Manrique‐Acevedo, C., Hirsch, I. B., & Eckel, R. H. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2311526 · Cited by 79
Pasqua, M.-R., Tsoukas, M. A., Kobayati, A., Aboznadah, W., Jafar, A., & Haidar, A. (2025) · Nature Medicine · doi:10.1038/s41591-024-03463-z · Cited by 68
“The reduction in HbA1c in our study was larger than what has been reported with liraglutide 23,24 .”
InfluentialDanne, T., Cariou, B., Buse, J. B., Garg, S. K., Rosenstock, J., Banks, P. L., Kushner, J. A., McGuire, D. K., Peters, A. L., Sawhney, S., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2149 · Cited by 66
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
Chamberlain, J. J., Kalyani, R. R., Leal, S., Rhinehart, A. S., Shubrook, J. H., SKOLNIK, N., & Herman, W. H. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1259 · Cited by 69
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Skra, J., Valensi, P. E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 60
Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 61
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
Guyton, J., Jeon, M., & Brooks, A. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz179 · Cited by 55
Pettus, J., BOEDER, S. C., Christiansen, M. P., Denham, D. S., Bailey, T. S., Aktürk, H. K., Klaff, L. J., Rosenstock, J., Cheng, M., Bode, B. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02011-x · Cited by 62
Self-citationDyńka, D., Kowalcze, K., Ambrożkiewicz, F., & Paziewska, A. (2023) · Nutrients · doi:10.3390/nu15030500 · Cited by 58
Ebrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Dejgaard, T., von Scholten, B. J., Christiansen, E., Kreiner, F., Bardtrum, L., von Herrath, M., Mathieu, C., & Madsbad, S. (2021) · Diabetes, obesity and metabolism · doi:10.1111/dom.14532 · Cited by 42
Self-citationSchnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 52
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans, M., Hicks, D., Patel, D., Patel, V., McEwan, P. C., & Dashora, U. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00728-6 · Cited by 48
Pozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
“Two randomized, placebo-controlled, double-blind studies, which were not included in the meta-analysis, assessed liraglutide in patients with type 1 diabetes (10; 11).”
BackgroundThe role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
“The ADJUNCT ONE trial (Effi cacy and Safety of Lira-glutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes), 55 the ADJUNCT TWO trial, 56 and a large meta-analysis 57 found reductions in hemoglobin A1c, body weight, and total daily dose of insulin, but also highlighted an…”
BackgroundReducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Avgerinos, I., Manolopoulos, A., Michailidis, T., Kitsios, K., Liakos, A., Karagiannis, T., Dimitrakopoulos, K., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14291 · Cited by 48
Maffei, P., Bettini, S., Busetto, L., & Dassie, F. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s240903 · Cited by 49
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, X., Pan, X., Wu, X., Zheng, S., Chen, Y., Liu, D., & Zhang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.975880 · Cited by 44
Rydén, A. K., Perdue, N., Pagni, P. P., Gibson, C. B., Ratliff, S. S., Kirk, R. K., Friesen, T. J., Haase, C., Coppieters, K. T., von Herrath, M. G., et al. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.006 · Cited by 45
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Klein, K. R., Freeman, J. L. R., Dunn, I. M., Dvergsten, C., Kirkman, M. S., Buse, J. B., Valcarce, C., Buse, J. B., Klein, K. R., Kirkman, M. S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2684 · Cited by 44
Self-citationThe future of type 1 diabetes therapy
Ziegler, A.-G., Cengiz, E., & Kay, T. W. H. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01438-2 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
Shimada, A., Hanafusa, T., Yasui, A., Lee, G., Taneda, Y., Sarashina, A., Shiki, K., George, J. T., Soleymanlou, N., & Marquard, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13351 · Cited by 44
Herold, K. C., Reynolds, J., Dziura, J. D., Baidal, D. A., Gaglia, J. L., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14121 · Cited by 47
Frandsen, C. S., Dejgaard, T. F., Andersen, H. U., Holst, J. J., Hartmann, B., Thorsteinsson, B., & Madsbad, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12830 · Cited by 46
Recent trends and advances in type 1 diabetes therapeutics: A comprehensive review
Singh, A. K., Afshan, N., Singh, A., Singh, S. K., Yadav, S., Kumar, M., Sarma, D. K., & Verma, V. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151329 · Cited by 47
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13063 · Cited by 38
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Glycemic Management in Adults With Type 1 Diabetes
McGibbon, A., Adams, L., Ingersoll, K. S., Kader, T., & Tugwell, B. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.012 · Cited by 58
Leahy, J. (. L., Aleppo, G., Fonseca, V. A., Garg, S. K., Hirsch, I. B., McCall, A. L., McGill, J. B., & Polonsky, W. H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00222 · Cited by 34
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“12,13 This is most likely due to depression of glucagon levels after meals and reduced postprandial glucose excursions.”
InfluentialTirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial
SNAITH, J. R., Frampton, R., Samocha‐Bonet, D., & Greenfield, J. R. (2025) · Diabetes Care · doi:10.2337/dc25-2379 · Cited by 51
Adjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
Kobayati, A., Haidar, A., & Tsoukas, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14637 · Cited by 39
Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes
Aktürk, H. K., Rewers, A. H., Joseph, H., Schneider, N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0114 · Cited by 38
Baker, C., Wason, S., Banks, P. L., Sawhney, S., Chang, A., Danne, T., Gesty‐Palmer, D., Kushner, J. A., McGuire, D. K., Mikell, F. L., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13825 · Cited by 30
Schmidt, S., Frandsen, C. S., Dejgaard, T. F., Vistisen, D., Halldórsson, T., Olsen, S. F., Jensen, J. B., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14567 · Cited by 29
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
Dejgaard, T. F., Frandsen, C. S., Kielgast, U., Størling, J., Overgaard, A. J., Svane, M. S., Olsen, M. H., Thorsteinsson, B., Andersen, H. U., Krarup, T., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15889 · Cited by 29
Immune cell–adipose tissue crosstalk in metabolic diseases with a focus on type 1 diabetes
Alzaïd, F., Fagherazzi, G., Riveline, J., Bahman, F., Al‐Rashed, F., Al‐Mulla, F., & Ahmad, R. (2025) · Diabetologia · doi:10.1007/s00125-025-06437-z · Cited by 34
Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes
Garg, M., Ghanim, H., Kuhadiya, N. D., Green, K., HEJNA, J. M., Abuaysheh, S., Torre, B., Batra, M., Makdissi, A., Chaudhuri, A., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12944 · Cited by 26
Ketogenic diets in the management of type 1 diabetes: Safe or safety concern?
Buehler, L. A., Noe, D. R., Knapp, S., Isaacs, D. M., & Pantalone, K. M. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20121 · Cited by 33
Thivolet, C. H., Marchand, L., & Chikh, K. (2019) · Diabetologia · doi:10.1007/s00125-018-4804-y · Cited by 30
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 29
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
Liu, L., Shao, Z., Xia, Y., Qin, J., Xiao, Y., Zhou, Z., & Mei, Z. (2019) · Endocrine Connections · doi:10.1530/ec-18-0546 · Cited by 25
Dubé, M., D'Amours, M., & Weisnagel, S. J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14050 · Cited by 28
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Warnes, H., Helliwell, R., Pearson, S. M., & Ajjan, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0496-z · Cited by 27
GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
Nauck, M. A., & Meier, J. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30043-7 · Cited by 24
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight
Grassi, B. A., Onetto, M. T., Sánchez, C., Tapia, N., & Salas, F. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111593 · Cited by 26
Delrue, C., & Speeckaert, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179351 · Cited by 28
Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
Metadata
- Authors
- Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Mount Sinai Hospital (CA)
- Capio St. Görans Hospital and the Karolinska Institute, Stockholm, Sweden
- Health Sciences Centre (CA)
- The Royal Melbourne Hospital (AU)
- Novo Nordisk (Denmark) (DK)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Mathieu, Chantal
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-09
- Volume
- 39
- Issue
- 10
- Pages
- 1702-1710
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514658869
- Cited by
- 347
- References
- 26
- Citations by year
- 2026: 52 · 2025: 56 · 2024: 49 · 2023: 28 · 2022: 23 · 2021: 28 · 2020: 34 · 2019: 27 · 2018: 26 · 2017: 17 · 2016: 7
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- Novo Nordisk A/S (NN9211-3919)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, insulin therapy, glycemic control, HbA1c, insulin dose reduction, weight loss, GLP-1 receptor agonists, adjunctive therapy, drug safety, hypoglycemia, nausea, gastrointestinal adverse effects, drug discontinuation
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.